Skip to main content

DNAVision to Use Roche s AmpliChip CYP450 Test

NEW YORK, Nov. 3 (GenomeWeb News) - DNAVision will begin service of Roche Diagnostics' AmpliChip CYP450 test, the company said today.

 

The AmpliChip CYP450, which is built upon the Affymetrix microarray platform, analyzes the cytochrome P450 2D6 and 2C19 genotypes to help determine the appropriate dosages of medications for a variety of conditions, including pain medication, cardiac disease, cancer, and depression.

 

"DNAVision is proud to be chosen by Roche Diagnostics Belgium as the first European pharmacogenomic private testing laboratory to provide this first FDA approved DNA microarray test" said Arnaud Termonia, scientific advisor of DNAVision, in a statement.

 

The U.S. Food and Drug Administration cleared the AmpliChip CYP450 test for diagnostic use earlier this year.

 

 

 

 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.